NPM1 and acute myeloid leukemia: In our ex vivo tests, NPM1-mutated AML cells showed an increased sensitivity to Nut-3a and the drug combination compared with NPM1-wt cases (excluding TP53-mut patients), suggesting a potential vulnerability.